Back to Urethra Transitional Cell Carcinoma

Urethra Transitional Cell Carcinoma — Clinical Trials

MONDO:000283611 active·1 recruitingLast updated: Mar 16, 2026, 4:50 AM

Trial Landscape

Urethra Transitional Cell Carcinoma has a growing clinical research program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment8

Procedure6

Biological Therapy6

3 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Sponsor Types

Academic/Other6NIH5

Trial Locations

United States11 trials

Canada3 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

11 Trials

Phase 2Recruiting

NCT05987241

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Feb 2024Est. completion: Sep 2030Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT05092958

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2022Est. completion: Jun 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT04637594

Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy

Sponsor:Alliance for Clinical Trials in Oncology

United StatesStarted: May 2022Est. completion: Sep 2030Updated: Jan 2025

Phase 2Active, Not Recruiting

NCT03237780

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2018Est. completion: Jun 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04940299

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Sep 2021Est. completion: Dec 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04848519

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Sponsor:Emory University

United StatesStarted: May 2021Est. completion: Dec 2026Updated: Feb 2026

Phase 2Active, Not Recruiting

NCT04953104

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Sep 2021Est. completion: Dec 2026Updated: Oct 2025

Phase 1Active, Not Recruiting

NCT04963153

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2022Est. completion: Dec 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

NCT02496208

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2015Est. completion: Sep 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

NCT03582475

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Sponsor:Jonsson Comprehensive Cancer Center

United StatesStarted: Jan 2019Est. completion: Dec 2026Updated: Nov 2025

Early Phase 1Active, Not Recruiting

NCT02812420

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Mar 2017Est. completion: Dec 2027Updated: Mar 2026

Stay informed about clinical trials for Urethra Transitional Cell Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 4:50 AM

Urethra Transitional Cell Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Trial Locations

11 Trials

Open Trials1

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Active Trials10

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery